NICE Rejects Adjuvant Perjeta in HER2 Breast Cancer

(MedPage Today) -- In contrast with FDA, Britain ' s cost watchdog says drug may not offer ' meaningful ' benefit
Source: MedPage Today Public Health - Category: American Health Source Type: news